Navigation Links
Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms
Date:10/16/2007

SYDNEY, Australia, Oct. 16 /PRNewswire-FirstCall/ -- Starpharma Holdings Ltd (ASX: SPL, Pink Sheets: SPHRY) today announced the signing of an agreement with SSL International plc (LSE: SSL), owner of Durex(R), the world's leading condom brand.

The agreement, under which a commercial licence will be negotiated, sets out a co-development program for condoms with a VivaGel(R) coating. Undisclosed fees are payable to Starpharma under the co-development agreement, which also provides for the commencement of regulatory and market development activities by the two parties.

SSL is the world's largest manufacturer of condoms with approximately 30% share of the global market for branded condom sales, selling into over 100 countries around the world. Global condom retail sales in 2005 were approximately $3.2 billion(1)(1), with the top four companies representing as much as 70% of the market.

"We are delighted to be working with SSL, whom we believe will be an excellent co-development partner for VivaGel(R) as a condom coating," said Starpharma's Chief Executive Officer, Dr. Jackie Fairley. "In addition to SSL's unparalleled global commercial position and the strength of the Durex(R) brand, Starpharma also values the organisation's innovative approach, and its social-marketing program.

"Our development and commercialisation activities for VivaGel(R) are gathering momentum with this SSL agreement being the second of two unrelated condom coating agreements signed by Starpharma in the last three months," concluded Dr. Fairley.

VivaGel(R) has been shown to have potent contraceptive and microbicidal properties in animal studies, and is also under development as a stand-alone gel to prevent the transmission of STIs, including HIV and genital herpes.

About Starpharma:

Starpharma Holdings Limited (ASX: SPL, Pink Sheets: SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc. in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

For further information:

Media

Rebecca Wilson

Buchan Consulting

Tel: +61 2 9237 2800

Mob: +61 417 382 391

rwilson@bcg.com.au

Starpharma

http://www.starpharma.com

Dr. Jackie Fairley

Chief Executive Officer

+61 3 8532 2704

Ben Rogers

Company Secretary

+61 3 8532 2702

ben.rogers@starpharma.com

(1)(1) "Condoms: A Global Strategic Business Report", March 2005, Global Industry Analysts Inc.


'/>"/>
SOURCE Starpharma Holdings Limited
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Starpharma Develops New Gel (Vivagel) To Prevent HIV Transmission
2. Agreement To Speed Up Development of Bird flu vaccine
3. MIOT Hospital Signs Agreement With German Healthcare Facility
4. Indo-Fiji Agreement in Field of Health, Medicine Approved
5. Strained Economic Agreement Between Singapore And India
6. Ranbaxy Signs Agreement With Zenotech For Cancer Drugs
7. Subsidies For GPs Visits : Agreement Reached
8. Agreement for Joint Trials of Avian Flu Vac cine on Humans
9. Ranbaxy Signs Licensing, Supply Agreement for Canadian Market
10. Publishers John Wiley & Sons Enter Into An Agreement With NASPGHAN And AASLD
11. Medical Training Must Be Core Component Of Health Care Agreements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , ... December 06, 2016 , ... 'Tis the season ... daily routines. That means it's also the season when eating healthy, staying active, and ... diabetes) on schedule is harder to do. , "Shopping trips, parties and family ...
(Date:12/6/2016)... ... , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating to SpinLife, a ... to people who need help getting around. For some, advancing age has led to ... rehabilitation after an illness or accident. There is a wide variety of scooters, from ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... What: Shriners ... of the North Pole to our patients – using a video monitor and web-enabled ... The hospital will transform the Auditorium into a Christmas Wonderland, which is where the ...
(Date:12/5/2016)... ... ... For many years, Andrew G. Zubinas has accumulated over 130 ... the Lithuanian language and its poetry inspired him in writing “ Forest ... all aspects of a living, breathing forest where nothing ever stays the same. His ...
(Date:12/5/2016)... Novato, CA (PRWEB) , ... December 05, 2016 ... ... company, has extended its partnership with leading global lifestyle design firm kathy ireland® ... , Worldwise® and kathy ireland® Worldwide entered into an exclusive licensing agreement three ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... United Kingdom , Dec. 5, 2016   ... leading global specialty pharmaceutical company, today announced that it ... 2017 Corporate Equality Index (CEI), a national benchmarking survey ... lesbian, gay, bisexual and transgender (LGBT) workplace equality, administered ... the ranks of 517 major U.S. businesses which also ...
(Date:12/5/2016)... Dec. 5, 2016  Parallax Health Sciences, Inc. ("Parallax" ... announce that its pharmaceutical business, RoxSan Pharmacy, Inc. has ... coverage in all of the 42 states it is ... Michael Rashti Pharm . D, Pharmacist in Charge ... for our business. Medicare B spending last year came ...
(Date:12/5/2016)... Research and Markets has announced the addition of the ... Research, Disease Diagnostics), End User (Academic & Research Institutes, Pharmaceutical & ... offering. ... The western blotting market is expected ... in 2016, growing at a CAGR of 4.9%. ...
Breaking Medicine Technology: